Novartis is paying $1 billion upfront in a licensing deal for an experimental Huntington’s disease treatment from PTC ...

Swiss drugmaker Novartis will pay up to $2.9 billion for PTC Therapeutics' promising experimental drug for a neurological ...

Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...

Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

The Swiss pharmaceutical company invests in a PTC Therapeutics program to develop treatment for Huntington’s disease.

Shares of PTC Therapeutics surged Monday when the pharmaceutical firm announced it struck a nearly $2 billion license and ...

Ptc Therapeutics soars on the stock market with a +20% thanks to the exclusive agreement with Novartis for the PTC518 program against Huntington's disease. Agreement worth over 2,9 billion dollars. Ag ...

Shares of PTC Therapeutics Inc. climbed nearly 1% pre-market Tuesday, poised to extend their rally to levels last seen in ...

The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

In a report released today, Brian Abrahams from RBC Capital maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price ...